<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466749</url>
  </required_header>
  <id_info>
    <org_study_id>KY20172081</org_study_id>
    <nct_id>NCT03466749</nct_id>
  </id_info>
  <brief_title>Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China</brief_title>
  <acronym>RESPECT</acronym>
  <official_title>A Real-world Study in China: the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Union Hospital, Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Real-world study in China is evaluating the Safety and Efficacy of Paclitaxel&#xD;
      Eluting Balloon Catheter in Coronary de-novo lesions(target vessel&#xD;
      diameter:2.5mm-4.0mm)Treatment. And the primary point of this study is the target lesion&#xD;
      failure of 12 months after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TVF of 12 months after surgery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>target vessel failure of 12 months after surgery</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel Eluting Balloon Catheter treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel Eluting Balloon Catheter</intervention_name>
    <description>Paclitaxel Eluting Balloon Catheter</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-78 years of age, male or non-pregnant female;&#xD;
&#xD;
          2. patients with asymptomatic or symptomatic myocardial ischemia, stable or unstable&#xD;
             angina pectoris, myocardial infarction with a course of more than two weeks, and&#xD;
             patients with indications for percutaneous coronary intervention;&#xD;
&#xD;
          3. the target lesions were primary, in situ coronary artery stenosis, located on one or&#xD;
             two different coronary artery vessels, the number of target lesions on each coronary&#xD;
             artery was not more than one;&#xD;
&#xD;
          4. the length of the target lesion ≤ 26mm (visual), which can be covered by a single drug&#xD;
             balloon (it is suggested that the balloon should cover at least 4mm healthy partition,&#xD;
             2 mm at each end; The reference diameter of target vessel was 2.5mm-4.0mm (visual);&#xD;
&#xD;
          5. the stenosis degree of the target lesion was ≥ 70%;&#xD;
&#xD;
          6. left ventricular ejection fraction ≥ 45%.&#xD;
&#xD;
          7. patients who can understand the purpose of the trial, voluntarily participate and sign&#xD;
             informed consent, and are willing to follow up the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Related to patients:&#xD;
&#xD;
          1. patients with myocardial infarction within two weeks;&#xD;
&#xD;
          2. pregnant or lactating women;&#xD;
&#xD;
          3. cardiogenic shock, acute infection, known bleeding or coagulation disorder, or active&#xD;
             digestive tract; Patients with history of hemorrhage or ulcer, cerebral hemorrhage or&#xD;
             subarachnoid hemorrhage, stroke within half a year;&#xD;
&#xD;
          4. patients with a life expectancy less than one year or with difficulties in clinical&#xD;
             follow-up;&#xD;
&#xD;
          5. patients who had a history of PTCA or had other operations scheduled during the&#xD;
             follow-up period of one year;&#xD;
&#xD;
          6. patients who are participating in any other clinical study and who have not reached&#xD;
             the main end point of the study;&#xD;
&#xD;
          7. present or previous history of severe liver disease, and / or renal impairment: serum&#xD;
             creatinine &gt; 2.0 mg / dl( 176.8 umol / L) or undergoing hemodialysis therapy.&#xD;
             Therefore, it does not meet the requirements of angiography;&#xD;
&#xD;
          8. patients with left ventricular ejection fraction below 45%;&#xD;
&#xD;
          9. for other reasons, the researchers did not think it was appropriate for a patient to&#xD;
             be selected.&#xD;
&#xD;
        Related to lesions:&#xD;
&#xD;
          1. left main lesion and the bifurcation with side branch &gt;2.5 mm;&#xD;
&#xD;
          2. the location of the lesion was less than 10 mm at the proximal end of the anterior&#xD;
             descending branch, 5 mm in the circumflex branch and 5 mm in the proximal end of the&#xD;
             right coronary artery.&#xD;
&#xD;
          3. severe calcification and twisted lesions which can not be successfully predilated, are&#xD;
             not suitable for drug balloon delivery and expansion.&#xD;
&#xD;
          4. lesion length ≥ 26 mm;&#xD;
&#xD;
          5. evidence of severe thrombosis in target vessels before intervention;&#xD;
&#xD;
          6. lesions that cannot be treated with PTCA or other interventional techniques;&#xD;
&#xD;
          7. after predilation of the target lesion, residual stenosis ≥ 30% or TIMI blood flow &lt;&#xD;
             3, and / or obvious flow limiting dissection.&#xD;
&#xD;
        Exclusion criteria related to drugs:&#xD;
&#xD;
          1. patients with bleeding constitution, anticoagulant or antiplatelet drugs;&#xD;
&#xD;
          2. patients who cannot tolerate aspirin and / or clopidogrel or who have a history of&#xD;
             neutropenia or thrombocytopenia or who have too severe liver failure to receive&#xD;
             clopidogrel;&#xD;
&#xD;
          3. patients known to be intolerant or allergic to heparin, contrast agents, paclitaxel,&#xD;
             iopramide, rapamycin, polylactic acid-glycolic acid polymer, stainless steel, etc.&#xD;
&#xD;
          4. leukopenia (leukocyte count &lt; 3 × 109 / L and the course &gt; 3 days) or neutropenia ANC&#xD;
             &lt; 1000 neutrophil / mm3 and the course&gt; 3 days). Or patients had a history of&#xD;
             thrombocytopenia (&lt; 100,000 platelets / mm3;&#xD;
&#xD;
          5. patients with a history of peptic ulcer or gastrointestinal bleeding in the past 6&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Tao, Ph.D.,M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Tao, Ph.D.,M.D.</last_name>
    <phone>86-29-84775183</phone>
    <email>lingtao2006@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiyong Yin, Ph.D.,M.D.</last_name>
    <phone>86-29-84775183</phone>
    <email>zhiyong_yin@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ling Tao</name>
      <address>
        <city>Xi'an</city>
        <state>Shannxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Tao</last_name>
      <phone>+862984775183</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Ling Tao</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Coronary Disease</keyword>
  <keyword>Drug eluting balloon</keyword>
  <keyword>De-novo lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

